Claudio Montalto; Andrea Munafò; Francesco Soriano; Ketina Arslani; Stephanie Brunner; Sarah Verhemel; Ottavia Cozzi; Antonio Mangieri; Andrea Buono; Mattia Squillace; Stefano Nava; José Luis Díez Gil; Andrea Scotti; Marco Foroni; Giuseppe Esposito; Alessandro Mandurino-Mirizzi; David Bauer; Benjamin Ornelas; Pablo Codner; Kerstin Piayda; Italo Porto; Federico Marco; Horst Sievert; Ran Kornowski; Petr Tousek; Dionigi Fischetti; Azeem Latib; Jorge Sanchez; Diego Maffeo; Francesco Bedogni; Bernhard Reimers; Damiano Regazzoli; Nicolas Mieghem; Lars Søndergaard; Francesco Saia; Stefan Toggweiler; Ole Backer; Jacopo Oreglia

doi:10.4244/EIJ-D-24-00933

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

Original Research

DOI: 10.4244/EIJ-D-24-00933

Outcomes of complex, high-risk percutaneous coronary intervention in patients with severe aortic stenosis: the ASCoP registry

Claudio Montalto¹^,², MD; Andrea R. Munafò¹, MD; Francesco Soriano¹, MD; Ketina Arslani³^,⁴, MD; Stephanie Brunner⁵, MD; Sarah Verhemel⁶, MD; Ottavia Cozzi⁷, MD; Antonio Mangieri⁷, MD; Andrea Buono⁸, MD; Mattia Squillace⁹, MD; Stefano Nava¹, MD; José Luis Díez Gil¹⁰, MD; Andrea Scotti¹¹, MD; Marco Foroni¹², MD; Giuseppe Esposito¹, MD, PhD; Alessandro Mandurino-Mirizzi¹³, MD; David Bauer¹⁴, MD; Benjamin De Ornelas⁸, MD; Pablo Codner¹⁵, MD; Kerstin Piayda¹⁶, MD; Italo Porto¹⁷, MD, PhD; Federico De Marco¹⁸, MD, PhD; Horst Sievert¹⁶, MD; Ran Kornowski¹⁵, MD; Petr Tousek¹⁴, MD; Dionigi Fischetti¹³, MD; Azeem Latib¹¹, MD; Jorge Sanz Sanchez¹⁰, MD; Diego Maffeo⁸, MD; Francesco Bedogni⁹, MD; Bernhard Reimers⁷, MD; Damiano Regazzoli⁷, MD; Nicolas Van Mieghem⁶, MD, PhD; Lars Sondergaard¹⁹, MD; Francesco Saia¹², MD; Stefan Toggweiler⁵, MD; Ole De Backer³^,²⁰, MD, PhD; Jacopo A. Oreglia¹, MD

Abstract

Background: There is a lack of evidence to guide treatment of patients with a concomitant indication for transcatheter aortic valve implantation (TAVI) and complex, high-risk percutaneous coronary intervention (PCI).

Aims: We aimed to assess different strategies of PCI timing in this high-risk TAVI cohort.

Methods: The ASCoP registry retrospectively included patients with a clinical indication for both TAVI and PCI with at least 1 criterion of complex or high-risk PCI. The primary endpoint was a composite of all-cause death and unplanned rehospitalisation for cardiovascular causes. The secondary endpoint was a composite of all-cause death, stroke, acute myocardial infarction, major bleeding, major vascular complication and unplanned revascularisation. Multivariable analysis was used to adjust for possible confounders.

Results: A total of 519 patients were included: 363 (69.9%) underwent staged procedures and 156 (30.1%) concomitant TAVI and PCI. After 441 (interquartile range 182-824) days, the primary endpoint occurred in 151 (36.5%) cases, without any significant difference between the 2 groups (p=0.98), while the secondary endpoint occurred more frequently in the concomitant group (n=36 [25.8%] vs n=57 [17.4%]; p=0.014).

Conclusions: In patients undergoing TAVI and complex/high-risk PCI, a concomitant strategy is associated with a higher rate of adverse events and increased procedural risk. (ClinicalTrials.gov: NCT05750927)

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com